Viva Biotech Holdings (HKG:1873)
Hong Kong · Delayed Price · Currency is HKD 1.280
-0.050 (-3.76%)
Sep 11, 2026, 4:08 PM HKT
Viva Biotech Holdings Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,742 | 3,799 | 1,817 | 2,249 | 3,352 | 9,045 | |
Market Cap Growth | -52.20% | 109.02% | -19.19% | -32.91% | -62.94% | -48.29% |
Enterprise Value | 2,605 | 4,090 | 2,374 | 4,227 | 5,809 | 10,494 |
Last Close Price | 1.33 | 1.80 | 0.86 | 1.05 | 1.75 | 4.71 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.74 | 15.53 | 10.21 | - | - | 25.63 |
Forward PE | 6.83 | 5.15 | 5.15 | 5.15 | 5.17 | 10.88 |
PS Ratio | 1.25 | 1.97 | 0.86 | 0.95 | 1.25 | 3.50 |
PB Ratio | 0.60 | 0.85 | 0.45 | 0.55 | 0.82 | 1.88 |
P/TBV Ratio | 1.56 | 2.23 | 1.33 | 1.84 | 3.05 | 6.01 |
P/FCF Ratio | 7.86 | 30.73 | 9.32 | 10.43 | 21.69 | - |
P/OCF Ratio | 5.30 | 14.70 | 4.57 | 5.32 | 7.68 | 94.67 |
PEG Ratio | - | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.19 | 2.13 | 1.12 | 1.78 | 2.16 | 4.06 |
EV/EBITDA Ratio | 5.81 | 9.54 | 5.16 | 9.81 | 11.78 | 23.11 |
EV/EBIT Ratio | 12.23 | 19.02 | 9.71 | 19.92 | 19.32 | 36.09 |
EV/FCF Ratio | 7.47 | 33.10 | 12.17 | 19.61 | 37.58 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.23 | 0.33 | 0.34 | 0.52 | 0.78 | 0.68 |
Debt / EBITDA Ratio | 2.29 | 3.29 | 2.90 | 4.71 | 6.25 | 6.81 |
Debt / FCF Ratio | 2.97 | 11.98 | 7.01 | 9.72 | 20.65 | - |
Net Debt / Equity Ratio | -0.03 | 0.06 | 0.09 | 0.24 | 0.60 | 0.47 |
Net Debt / EBITDA Ratio | -0.34 | 0.63 | 0.79 | 2.22 | 4.91 | 5.01 |
Net Debt / FCF Ratio | -0.42 | 2.18 | 1.87 | 4.43 | 15.68 | -3.80 |
Asset Turnover | 0.28 | 0.24 | 0.27 | 0.28 | 0.30 | 0.26 |
Inventory Turnover | 3.48 | 3.53 | 4.88 | 4.84 | 5.61 | 7.33 |
Quick Ratio | 1.08 | 1.22 | 1.26 | 1.03 | 0.44 | 1.44 |
Current Ratio | 1.54 | 1.51 | 1.56 | 1.32 | 0.73 | 2.14 |
Return on Equity (ROE) | 5.62% | 6.88% | 5.92% | -2.74% | -13.41% | 7.84% |
Return on Assets (ROA) | 1.71% | 1.70% | 1.98% | 1.57% | 2.08% | 1.83% |
Return on Invested Capital (ROIC) | 4.25% | 3.89% | 3.96% | 3.74% | 4.62% | 4.04% |
Return on Capital Employed (ROCE) | 3.30% | 3.30% | 3.90% | 3.30% | 5.10% | 3.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.50% | 6.44% | 9.80% | -5.69% | -17.82% | 3.90% |
FCF Yield | 12.72% | 3.25% | 10.73% | 9.59% | 4.61% | -6.61% |
Payout Ratio | - | - | - | - | - | 5.66% |
Buyback Yield / Dilution | 25.76% | 18.44% | -41.39% | -5.91% | 2.81% | -25.41% |
Total Shareholder Return | 25.76% | 18.44% | -41.39% | -5.91% | 2.81% | -25.41% |